Luye Pharma Group’s wholly owned subsidiary Yantai Luye Drugs Trading has collaborated with Beijing Biostar Pharmaceuticals’ subsidiary Chengdu Biostar Pharmaceuticals for marketing anticancer drug, Utidelone Injection, in Chinese mainland.
Biopharmaceutical company Alvotech and BiosanaPharma have signed an exclusive global licensing agreement for the co-development of a proposed biosimilar, AVT23 (also called BP001), to Xolair (omalizumab).
US-based Ocugen has signed a letter of intent (LOI) to acquire Liminal Biosciences’ manufacturing site located in Belleville, Ontario, Canada, for an undisclosed sum.
Synthetic biotechnology company Amyris has agreed to acquire MenoLabs, a menopause symptoms treatment company.
Pfizer has completed the collaboration transaction with Biohaven Pharmaceuticals to obtain rights to market the latter’s rimegepant and zavegepant outside of the US.
Ovid Therapeutics has signed a license agreement with AstraZeneca for a library of early-stage small molecules that target the KCC2 transporter.
Ascletis Pharma is expanding the production of ritonavir oral tablets as well as the oral direct-acting antiviral R&D pipeline to treat SARS-CoV-2 virus amid the recent surge in Covid-19 cases.
Texas Children's Hospital and Baylor College of Medicine are set to launch Corbevax, a protein sub-unit Covid-19 vaccine in India, with plans to roll out in other underserved countries later.
Pfizer has signed an agreement to deliver an additional 2.5 million treatment courses of its investigational Covid-19 pill Paxlovid to the UK.
Novo Nordisk has announced plans to make more than $2.58bn (DKK17bn) investment to expand its manufacturing facilities in Kalundborg, Denmark.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.